{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:04:35Z","timestamp":1789016675575,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In parallel to the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO 2022), an alternative International Consensus Classification (ICC) has been proposed. To evaluate the impact of the new classifications on AML diagnoses and ELN-based risk classification, we analyzed 717 MDS and 734 AML non-therapy-related patients diagnosed according to the revised 4th WHO edition (WHO 2017) by whole genome and transcriptome sequencing. In both new classifications, the purely morphologically defined AML entities decreased from 13% to 5%. Myelodysplasia-related (MR) AML increased from 22% to 28% (WHO 2022) and 26% (ICC). Other genetically-defined AML remained the largest group, and the abandoned AML-\n                    <jats:italic>RUNX1<\/jats:italic>\n                    was mainly reclassified as AML-MR (WHO 2022: 77%; ICC: 96%). Different inclusion criteria of AML-\n                    <jats:italic>CEBPA<\/jats:italic>\n                    and AML-MR (\n                    <jats:italic>i.a<\/jats:italic>\n                    . exclusion of\n                    <jats:italic>TP53<\/jats:italic>\n                    mutated cases according to ICC) were associated with differences in overall survival. In conclusion, both classifications focus on more genetics-based definitions with similar basic concepts and a large degree of agreement. The remaining non-comparability (e.g.,\n                    <jats:italic>TP53<\/jats:italic>\n                    mutated AML) needs additional studies to definitely answer open questions on disease categorization in an unbiased way.\n                  <\/jats:p>","DOI":"10.1038\/s41375-023-01909-w","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T03:02:24Z","timestamp":1682737344000},"page":"1413-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["AML classification in the year 2023: How to avoid a Babylonian confusion of languages"],"prefix":"10.1038","volume":"37","author":[{"given":"Sandra","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-1551","authenticated-orcid":false,"given":"Constance","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-3265","authenticated-orcid":false,"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pohlkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-2874","authenticated-orcid":false,"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-2837","authenticated-orcid":false,"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-4380","authenticated-orcid":false,"given":"Gregor","family":"Hoermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"1909_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Myelodysplastic syndromes. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 97\u2013120."},{"key":"1909_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia."},{"key":"1909_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","volume":"125","author":"RC Lindsley","year":"2015","unstructured":"Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367\u201376.","journal-title":"Blood."},{"key":"1909_CR4","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ajcp\/aqab172","volume":"157","author":"Y Gao","year":"2021","unstructured":"Gao Y, Jia M, Mao Y, Cai H, Jiang X, Cao X, et al. Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and De Novo Acute Myeloid Leukemia. Am J Clin Pathol. 2021;157:691\u2013700.","journal-title":"Am J Clin Pathol"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood."},{"key":"1909_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood."},{"key":"1909_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood."},{"key":"1909_CR8","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","volume":"247","author":"FE Harrell Jr","year":"1982","unstructured":"Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. Jama. 1982;247:2543\u20136.","journal-title":"Jama."},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87\u2013103.","journal-title":"Blood."},{"key":"1909_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/bloodadvances.2021004292","volume":"6","author":"S Wakita","year":"2022","unstructured":"Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022;6:238\u201347.","journal-title":"Blood Adv"},{"key":"1909_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood.2020009652","volume":"138","author":"K Tarlock","year":"2021","unstructured":"Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: A report from the Children\u2019s Oncology Group. Blood. 2021;138:1137\u201347.","journal-title":"Blood."},{"key":"1909_CR12","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1080\/10428194.2020.1737689","volume":"61","author":"I Summerer","year":"2020","unstructured":"Summerer I, Haferlach C, Meggendorfer M, Kern W, Haferlach T, Stengel A. Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count. Leuk Lymphoma. 2020;61:1756\u20139.","journal-title":"Leuk Lymphoma"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/gcc.23004","volume":"61","author":"J Gao","year":"2022","unstructured":"Gao J, Gurbuxani S, Zak T, Kocherginsky M, Ji P, Wehbe F, et al. Comparison of myeloid neoplasms with nonclassic 3q26.2\/MECOM versus classic inv(3)\/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation. Genes Chromosomes Cancer. 2022;61:71\u201380.","journal-title":"Genes Chromosomes Cancer"},{"key":"1909_CR14","first-page":"162","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood. Cancer Journal. 2021;11:162.","journal-title":"Cancer Journal"},{"key":"1909_CR15","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1038\/leu.2016.126","volume":"30","author":"VI Gaidzik","year":"2016","unstructured":"Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30:2160\u20138.","journal-title":"Leukemia."},{"key":"1909_CR16","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","volume":"123","author":"JE Lancet","year":"2014","unstructured":"Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML. Blood. 2014;123:3239\u201346.","journal-title":"Blood."},{"key":"1909_CR17","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"1909_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1080\/10428194.2019.1660970","volume":"61","author":"M Alfayez","year":"2020","unstructured":"Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, Daver N. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020;61:288\u201397.","journal-title":"Leuk Lymphoma"},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1182\/blood-2018-99-117772","volume":"132","author":"AD Goldberg","year":"2018","unstructured":"Goldberg AD, Talati C, Desai P, Famulare C, Devlin SM, Farnoud N, et al. TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia. Blood. 2018;132:1433.","journal-title":"Blood."},{"key":"1909_CR20","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","volume":"6","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML. Blood Adv. 2022;6:2847\u201353.","journal-title":"Blood Adv"},{"key":"1909_CR21","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139:2347\u201354.","journal-title":"Blood."},{"key":"1909_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cncr.34535","volume":"129","author":"RM Shallis","year":"2023","unstructured":"Shallis RM, Daver NG, Altman JK, Hasserjian RP, Kantarjian HM, Platzbecker U, et al. TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer. 2023;129:175\u201380.","journal-title":"Cancer."},{"key":"1909_CR23","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/leu.2016.263","volume":"31","author":"A Stengel","year":"2017","unstructured":"Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705\u201311.","journal-title":"Leukemia."},{"key":"1909_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood.2021013983","volume":"140","author":"M Tashakori","year":"2022","unstructured":"Tashakori M, Kadia T, Loghavi S, Daver N, Kanagal-Shamanna R, Pierce S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140:58\u201372.","journal-title":"Blood."},{"key":"1909_CR25","doi-asserted-by":"publisher","unstructured":"Bahaj W, Kewan T, Gurnari C, Durmaz A, Ponvilawan B, Pandit I, et al. Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia. Res Sq [Preprint]. 2023;https:\/\/doi.org\/10.21203\/rs.3.rs-2656206\/v1.","DOI":"10.21203\/rs.3.rs-2656206\/v1"},{"key":"1909_CR26","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","volume":"36","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, et al. Finding consistency in classifications of myeloid neoplasms: A perspective on behalf of the International workshop for myelodysplastic syndromes. Leukemia. 2022;36:2939\u201346.","journal-title":"Leukemia."},{"key":"1909_CR27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009010","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA, Long N, Saultz JN, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2022. https:\/\/doi.org\/10.1182\/bloodadvances.2022009010.","journal-title":"Blood Adv"},{"key":"1909_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00764-9","volume":"12","author":"M Jentzsch","year":"2022","unstructured":"Jentzsch M, Bischof L, Ussmann J, Backhaus D, Brauer D, Metzeler KH, et al. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation. Blood Cancer J. 2022;12:170.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01909-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01909-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T10:02:38Z","timestamp":1688378558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01909-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01909-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CH, WK and TH declare part ownership of Munich Leukemia Laboratory (MLL). SH, CB, StH, FD, MM, CP, and GH are employed by the MLL.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}